All In Biotech

Drug Trial Radar · NCT06526819

SMP-3124LP in Adults With Advanced Solid Tumors

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 14, 2024

Primary completion

Dec 2028

Study completion May 2029

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Conditions

  • Solid Tumor

Interventions

  • SMP3124LPDrug

    Liposomal encapsulation formulation of SMP-3124

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of the Recommended Phase 2 Dose by Assessing Dose-limiting Toxicities (DLTs)Time frame: 28 days
  2. Number of Participants With Adverse Events and Serious Adverse EventsTime frame: 6 months
  3. Determine the Objective Response Rate (ORR)Time frame: 6 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Not yet recruiting

  • Sarah Cannon Research Institute at HealthOne

    Denver, Colorado · Recruiting

  • Advent Health

    Celebration, Florida · Recruiting

  • Northwestern Medicine Cancer Center

    Chicago, Illinois · Recruiting

  • The University of Chicago

    Chicago, Illinois · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • National Cancer Center Hospital East

    Kashiwa-shi, Japan · Recruiting

  • Kyoto University Hospital

    Kyoto, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.